Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 3;17(8):2593-2594.
doi: 10.1080/21645515.2021.1891816. Epub 2021 Mar 2.

Letter to the editor concerning the article 'Safety of vaccines administration in hereditary fructose intolerance'

Affiliations

Letter to the editor concerning the article 'Safety of vaccines administration in hereditary fructose intolerance'

Rebeca Saborido-Fiaño et al. Hum Vaccin Immunother. .

Abstract

The most important approach for the management of hereditary fructose intolerance is a strict avoidance of fructose, sucrose and sorbitol from the diet and medications. A safe threshold of 2.4 mg/kg/dose was recently established by the Instituto Superiore di Sanità of Italy for both oral and parenteral routes, thus shouldering a safe administration of a majority of vaccines in these patients. This would not include, Rotarix® pre-established oral suspension and Rotateq® vaccines, which are indeed contraindicated. Moreover, Rotarix® white powder and solvent for oral suspension would only be safely administered at a weight above 9.3 kg.Overall, these recommendations to avoid rotavirus vaccination are difficult to implement because these vaccines are given during exclusive breastfeeding, prior to fructose-containing food introduction.

Keywords: Rotavirus; hereditary fructose intolerance; safety; vaccine.

PubMed Disclaimer

Comment in

References

    1. Mariorana A, Sabia A, Corsetti T, Dionisi-Vici C.. Safety of vaccines administration in hereditary fructose intolerance. Orphanet J Rare Dis. 2020;1(15(1)):274. doi:10.1186/s13023-020-01552-z. - DOI - PMC - PubMed
    1. Gallo G, Mel R, Ros E, Filia A, Ed. Guida alle controindicazioni alle vaccinazioni (aggiornamento 2018). Roma (Italy): Istituto Superiore di Sanità; 2019. (Rapporti ISTISAN 19/3).
    1. European Medicines Agency . Rotarix product information. Annex I-Summary of product characteristics. Last updated:2020. https://www.ema.europa.eu/en/documents/product-information/rotarix-epar-...
    1. Tate JE, Simonsen L, Viboud C, Steiner C, Patel MM, Curns AT, Parashar UD. Trends in intussusception hospitalizations among US infants, 1993-2004: implications for monitoring the safety of the new rotavirus vaccination program. Pediatrics. 2008;121(5):e1125–32. doi:10.1542/peds.2007-1590. - DOI - PMC - PubMed
    1. Burnett E, Parashar U, Tate J. Rotavirus vaccines: effectiveness, safety and future directions. Paediatr Drugs. 2018Jun;20(3):223–33. doi:10.1007/s40272-018-0283-3. - DOI - PMC - PubMed

LinkOut - more resources